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Objective: To assess 3-year data on the efficacy and safety of a new 52-mg levonorgestrel intrauterine contraceptive (LNG20) designed for
up to 7 years use.
Study Design: Nulliparous and parous women aged 16–45 years at enrollment with regular menstrual cycles and requesting contraception were
enrolled in an open-label, partially randomized trial to evaluate LNG20. The primary outcome was pregnancy rate for women aged 16–35 years
calculated as the Pearl Index.Women aged 36–45 years received LNG20 for safety evaluation only. All participants had in-person or phone follow-up
approximately every 3 months during the study.
Results: A total of 1600 women aged 16–35 years and 151 women aged 36–45 years agreed to LNG20 placement, including 1011 (57.7%)
nulliparous and 438 (25.1%) obese women. Successful placement occurred in 1714 (97.9%) women. Six pregnancies occurred, four of which
were ectopic. The Pearl Index for LNG20 was 0.15 (95% CI 0.02–0.55) through Year 1, 0.26 (95% CI 0.10–0.57) through Year 2, and 0.22
(95% CI 0.08–0.49) through Year 3. The cumulative life-table pregnancy rate was 0.55 (95% CI 0.24–1.23) through 3 years. Expulsion was
reported in 62 (3.5%) participants, most (50 [80.6%]) during the first year of use. Of women who discontinued LNG20 and desired
pregnancy, 86.8% conceived spontaneously within 12 months. Pelvic infection was diagnosed in 10 (0.6%) women. Only 26 (1.5%) LNG20
users discontinued due to bleeding complaints.
Conclusion: The LNG20 intrauterine system is highly effective and safe over 3 years of use in nulliparous and parous women.
Implications statement: A new 52-mg levonorgestrel-releasing intrauterine system is effective and safe for nulliparous and parous women
for at least 3 years.
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In the United States, more than half (51%) of approxi-
mately 6.6 million pregnancies each year are unintended
with 40% of unintended pregnancies ending in abortion [1].
Women who use copper intrauterine devices (IUD),
hormonal intrauterine systems (IUS) and contraceptive
implants have substantially lower rates of unintended
pregnancy than women using other methods of reversible
contraception [2]. Intrauterine contraceptives are used bye CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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however, only 7.7% of women practicing contraception use
intrauterine products [4]. Intrauterine contraceptives can
prevent pregnancy for several years, with efficacy equivalent
to contraceptive sterilization [5]. When intrauterine contra-
ceptives are removed, the return to fertility is rapid [6–8].
Overall, intrauterine contraceptives are among the safest and
most cost effective contraceptive methods [9].
Socioeconomic level has an important relationship to
unintended pregnancy. Women with household incomes
below 200% of the Federal Poverty Level have a 5.3-fold
greater risk of unintended pregnancy than women with
higher incomes [1]. This disparity has increased from a
2.5-fold difference in 1994 [1,10]. Women of lower
socioeconomic levels may have particular difficulty in
accessing highly effective contraceptives due to cost or
lack of insurance [11].
ACCESS IUS (A Comprehensive Contraceptive Efficacy
and Safety Study of an IUS) was designed to assess efficacy and
safety of a branded levonorgestrel-releasing IUS (LNG20) for
up to 7 years of contraception in a diverse population of women.
This study was conducted by Medicines360, a non-profit
women's health pharmaceutical company founded to expand
access to quality women's health products including LNG20.
This report includes the initial data submitted to the U.S. Food
and Drug Administration (FDA) for a 3-year indication of use
and includes efficacy data based on participation for up to 36
months through 19 December 2014 and safety data, regardless
of total duration of use, for all participants through 30May2014.2. Materials and methods
The ACCESS IUS multicenter, Phase 3, open-label
clinical trial was conducted at 29 clinical sites in the United
States, including public, private and university centers. The
study was approved by a central or local Institutional Review
Board for each center, as applicable. All women signed
written informed consent before study participation. The
study was registered with Clinicaltrials.gov, identifier
number NCT00995150. An independent data-safety moni-
toring committee reviewed the data every 6 months.
Enrollment began in December 2009 as a randomized
trial comparing LNG20 (LilettaTM; Medicines360, San
Francisco, CA, USA, and Actavis, Parsippany, NJ, USA;
LilettaTM is a trademark of Odyssea Pharma SPRL
[Belgium], an Actavis affiliate) to the currently marketed
levonorgestrel 52 mg IUS (Mirena®; Bayer Healthcare,
Whippany, NJ, USA) in a 4:1 ratio. LNG20 has a T-frame
measuring 32 by 32 mm with a release rate-controlling
membrane over a reservoir containing 52 mg levonorgestrel.
Mirena was included as an informational safety comparator
as initially required for an intended non-U.S. filing without
plans for formal or informal comparisons. After enrolling
159 of the planned 400 Mirena participants, it was
determined that this comparator group would no longer beneeded for the non-U.S. filing; thus, further enrollment was
limited to LNG20 only. Because the Mirena cohort was not
large enough for effectiveness calculations or statistically
meaningful comparisons, those data are not presented.
Healthy, non-pregnant, sexually active (at least four times
monthly), nulliparous and parous women aged 16–45 years
(inclusive) with regular menstrual cycles (21–35 days when
not using hormones and with a variation of typical cycle
length of no more than 5 days) were invited to participate.
Exclusion criteria ensured good general health, potential
fertility and low risk with IUS use and did not include any
restrictions on weight or body mass index (See Appendix 1).
At the screening visit and after signing informed consent,
participants provided a medical history and underwent blood
testing for hemoglobin level and liver and kidney function
and a pelvic exam to ensure all study criteria were met.
Women without a documented normal Pap test within the
past 18 months had testing performed. All participants had
Chlamydia testing; women who had no gonorrhea testing
since starting their current sexual relationship also had
gonorrhea testing. Women with a positive Chlamydia or
gonorrhea test at baseline or during the study were treated
with oral antibiotics without requirement for IUS removal.
Enrollment and IUS placement could occur on the same
day as the screening procedures. IUS placement was not
delayed to obtain Chlamydia or gonorrhea testing results. In
general, IUS placement could occur at any time in eligible
participants using a hormonal contraceptive or intrauterine
contraceptive (which was to be removed prior to study IUS
placement) or during the first 7 days of the menstrual cycle
for women using other contraceptive methods. Study staff
contacted an Interactive Voice Response System which
assigned the IUS to be placed and tracked subject enrollment
centrally. A statistician with no clinical role in conduct of the
study performed the randomization initially used for product
assignment. IUS placement was only attempted in women if
the uterus was successfully sounded to 5.5 cm or more. Up to
two placement attempts could occur within 30 days of
signing consent. Information on how to check for the IUS
strings was provided but the women were not required to
routinely check the strings. Participants received a diary for
daily recording of spotting, bleeding, cramping and other
contraceptive use for the first 24 months; thereafter, they
only recorded additional contraceptive use.
Follow-up visits were scheduled at 1, 3 and 6 months after
LNG20 placement and every 6 months thereafter to assess
adverse events, changes in sexual partner, medical history,
concomitant medication use and whether LNG20 was still
the primary method of contraception. Each follow-up visit
included a review of diaries, a urine pregnancy test and
measurement of vital signs. IUS presence was confirmed by
palpation or direct visualization of the strings; women with
missing strings underwent transvaginal ultrasonography to
confirm IUS presence at that visit and at subsequent annual
visits. Partial IUS expulsion was defined a priori as visual
evidence of the lower portion of the IUS stem protruding
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and/or cramping with the presence of the IUS in the lower
uterine segment or cervix. Pap testing [12] and sexually
transmitted disease screening [13] were performed when
clinically indicated; hemoglobin testing was repeated at
month 12 and study exit. Women who opted to discontinue
LNG20 use, experienced expulsion or were diagnosed with
pregnancy had a discontinuation office visit with the same
evaluations and IUS removal (if still in place). Starting at
Month 9, telephone contacts occurred 3 months after each
clinic visit to ask the same questions as at study visits.
A follow-up visit was scheduled 30–43 days after
discontinuing the study treatment for safety assessments.
Further follow-up was conducted up to 3 months for return
of spontaneous menses in women who elected to start a
non-hormonal contraceptive method or no contraception.
Women who desired pregnancy were followed up to 12
months to assess return to fertility.
The sample size was selected to meet U.S. FDA criteria
for product approval based on efficacy (Pearl Index) and
having at least 200 women reach the desired duration of use
among women 16–35 years old at study entry. The Pearl
Index at each year was required to have a two-sided 95% CI
such that the upper limit of the CI was no more than one
point greater than the Pearl Index point estimate. To meet
these requirements, 1600 women were enrolled in the main
LNG20 study arm assessing pregnancy and safety. An
additional 151 women 36–45 years were enrolled in a
non-randomized cohort for LNG20 safety only.
The primary outcome was on-treatment pregnancy, which
was defined as any pregnancy with a date of conception
beginning with the day of LNG20 placement and through 7
days after IUS discontinuation. Pregnancies were identified
through subject query, urine testing and confirmatory serum
pregnancy testing. A transvaginal ultrasound was performed
for pregnancy dating and to verify IUS presence. On-
treatment pregnancies were followed to completion.
Pregnancy rates were calculated as the Pearl Index
(number of pregnancies per 100 woman-years) for individual
years and cumulatively over three years including only
months during which women did not report any other
contraceptive use. If, however, a pregnancy occurred during
a month with additional contraceptive use, that month was
included in the denominator. Pregnancies among women in
whom an expulsion was not identified prior to the pregnancy
diagnosis were included as product failures. Secondary
efficacy outcomes included life-table failure rates calculated
using the Kaplan-Meier method, and Pearl Index and
life-table analyses without exclusion of months with other
contraceptive use.
Investigators at each study site assessed the severity of
adverse events (safety outcomes) and their relationship to the
IUS or to the placement or removal procedure. Adverse
events were organized into standardized terms using the
MedDRA (Medical Dictionary for Regulatory Activities) in
accordance with the International Conference on Harmoni-sation of Technical Requirements for Registration of
Pharmaceuticals for Human Use. Pelvic infection included
all women diagnosed by a clinician with endometritis or
pelvic inflammatory disease (PID). Fisher exact tests were
used when appropriate. Data were analyzed using SAS®
Software Version 9.3 (SAS Institute, Inc., Cary, NC, USA).3. Results
Of the 1751 who enrolled and were assigned to receive
LNG20, 1600 were 16–35 years old and 151 were 36–46
years old (Fig. 1). Demographic characteristics of the study
population appear in Table 1. Of note, 171 (9.8%) women
were using intrauterine contraception at enrollment, which
was removed prior to study product placement. Successful
placement occurred in 1714 (97.9%). Fifteen (0.9%)
participants did not have product placement attempted
because the uterus could not be sounded (n=9), the uterus
sounded to less than 5.5 cm (n=2), or problems occurred that
were unrelated to the product or inserter (n=4). Thus, the
successful LNG20 placement rate amongst those women
who had product placement attempted was 98.7%.
Among women 16–35 years of age, 31971 women-
months (34711 women-cycles) of LNG20 use are included
in the efficacy analysis. For the safety analysis of participants
16–45 years, 1412, 572 and 383 women had completed 1, 2
and 3 years of product use, respectively (Fig. 1). Overall, 614
(39.1%) 16–35 year olds and 47 (32.1%) 36–45 year olds
had discontinued study participation, most frequently for an
adverse event (n=215, 12.3%), lost to follow-up or
withdrawal of consent (n=137, 7.9%) or desiring pregnancy
(n=97, 5.5%).
Two pregnancies occurred in Year 1 and four in Year 2.
The pregnancies in Year 1 included one intrauterine
pregnancy after LNG20 expulsion and one ectopic pregnan-
cy associated with a perforation. The pregnancies in Year 2
included three ectopic pregnancies and one intrauterine
pregnancy which resulted in an early pregnancy failure.
Pregnancies occurred in two nulliparous and four parous
participants. The Pearl Index for LNG20 is 0.15 (95% CI
0.02–0.55) through year one, 0.26 (95% CI 0.10–0.57)
through year two, and 0.22 (95% CI 0.08–0.49) through year
3. The ectopic pregnancy rate through 3 years is 0.12 per
100-women years. Life-table analysis of 16–35 year olds
yielded a pregnancy rate of 0.14 (95% CI 0.04–0.57) through 1
year and 0.55 (95% CI 0.24–1.23) through 3 years. No
pregnancies occurred in LNG20 users 36–45 years of age.
Adverse reactions with a frequency of 5% or greater are
reported in Table 2. At least one adverse event was noted in
1333 (83.3%) of 16–35 year olds and 131 (86.8%) of 36–45
year olds. Few adverse events were considered by the
investigator to be related to LNG20 with an incidence N2%
(Table 3). The most common adverse events leading to
discontinuation were expulsion (3.5%), bleeding complaints
(1.5%), acne (1.3%) and mood swings (1.3%). Other adverse
Fig. 1. Disposition of participants in a phase 3 study investigating LNG20*.* The study is still ongoing; not all active participants have completed 2 years and 3
years of participation.† Enrollment was initiated in December 2009 as a randomized trial comparing LNG20 to the currently marketed levonorgestrel 52 mg IUS
(Mirena®, Bayer Healthcare, Whippany, NJ, USA) in a 4:1 ratio. Mirena enrollment was discontinued early in the trial after it was determined that this
comparator group would no longer be needed for non-U.S. approval submissions. Data from the Mirena cohort are not presented because the group was not large
enough for effectiveness calculations or statistically meaningful comparisons.
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than 1%. Discontinuation for all bleeding-related complaints
combined occurred in 26 (1.5%) LNG20 users. Fifty-nine
(3.4%) women had a symptomatic ovarian cyst, including
3.2% (32/986) of nulliparous women and 3.7% (27/728) of
parous women (p=.15). Only 5 (0.3%) participants
discontinued LNG20 use because of an ovarian cyst.
One death occurred in a LNG20 user due to a pre-existing
illness and was considered unrelated to the IUS by the site
principal investigator.
Uterine perforation was reported in 3 (0.17%) partici-
pants, all among women aged 16–35 years. One perfora-
tion occurred with uterine sounding after which placement
was not performed. The two (0.11%) perforations that
occurred with the IUS required surgical removal, one of
which was during treatment for an ectopic pregnancy.Expulsion was identified in 62 (3.5%) of the 1751
participants enrolled (3.6% of the 1714 with successful
placement) and occurred less frequently in nulliparous (20/
1011, 2.0%) women than parous (42/750, 5.6%) women
(pb.0001). Most expulsions (80.6%) occurred in the first
year of product use with 10 occurring within the first 30 days,
17 within the first 3 months, 30 within the first 6 months, and
50 within the first 12 months. Complete expulsions comprised
27 of the 62 expulsions (43.5%).
Site investigators reported pelvic infection in 10 (0.6%)
participants; seven infections were classified as PID and
three as endometritis by the site investigator. All 10
infections resolved with outpatient antibiotic treatment.
Four pelvic infections were diagnosed within 7 days, one
at day 39 and the other five more than 6 months following
IUS placement. Among cases classified as PID, two occurred
Table 1
Demographics of study population and contraceptive method at enrollment
for women enrolled in a phase 3 study investigating LNG20.
16–35 years old
(n=1600)
36–45 years old
(n=151)
Total
(n=1751)
Age (years) 26.2 ± 4.4 39.6 ± 2.7 27.3 ± 5.7
Ethnicity
Hispanic or Latina 237 (14.8) 21 (13.9) 258 (14.7)
Race
American Indian or
Alaska Native
19 (1.2) 2 (1.3) 21 (1.2)
Asian 61 (3.8) 7 (4.6) 68 (3.9)
Black or African
American
212 (13.3) 20 (13.2) 232 (13.3)
Native Hawaiian or
Other Pacific Islander
5 (0.3) 1 (0.7) 6 (0.3)
White 1250 (78.3) 120 (79.5) 1370 (78.4)
Multiple Races
Indicated
49 (3.1) 1 (0.7) 50 (2.9)
Body mass index
(kg/m2)⁎
26.8 ± 6.7 28.6 ± 7.6 26.9 ± 6.8
25–29.9 390 (24.4) 37 (24.5) 427 (24.4)
≥30 383 (24.0) 55 (36.4) 438 (25.1)
≥40 79 (4.9) 14 (9.3) 93 (5.3)
Partner status
Lives with partner 915 (57.2) 106 (70.2) 1021 (58.3)
Nulliparous 989 (61.8) 22 (14.6) 1011 (57.7)
Age (years) 24.8 ± 3.8 38.7 ± 3.0 25.1 ± 4.3
Parous 611 (38.2) 129 (85.4) 740 (42.3)
Age (years) 28.3 ± 4.5 39.8 ± 2.6 30.3 ± 6.1
Contraception at time of enrollment
Levonorgestrel IUS 111 (6.9) 30 (19.9) 141 (8.1)
Copper IUD 23 (1.4) 7 (4.6) 30 (1.7)
Implant 9 (0.6) 1 (0.7) 10 (0.6)
Combined hormonal
contraceptive
623 (38.9) 38 (25.2) 661 (37.7)
Progestin-only oral
contraceptive
32 (2.0) 3 (2.0) 35 (2.0)
Barrier method 576 (36.0) 45 (29.8) 621 (35.5)
Other 74 (4.6) 11 (7.3) 85 (4.9)
None 152 (9.5) 16 (10.6) 168 (9.6)
Data presented as n (%) or mean ± standard deviation.
⁎ Data missing for four 16–35 year old participants.
IUS = intrauterine system; IUD = intrauterine device.
able 2
dverse reactions occurring in ≥5% of LNG20 users over 3 years [n (%)].
16–35 years old
(n=1600)
36–45 years old
(n=151)
Total
(n=1751)
acterial vaginitis 212 (13.3) 26 (17.2) 238 (13.6)
ulvovaginal candidiasis 213 (13.3) 20 (13.2) 223 (13.3)
cne 203 (12.7) 12 (7.9) 215 (12.3)
eadache⁎ 151 (9.4) 21 (13.9) 172 (9.8)
ausea or vomiting 128 (8.0) 10 (6.6) 138 (7.9)
yspareunia 121 (7.6) 2 (1.3) 123 (7.0)
bdominal discomfort
or pain
110 (6.9) 9 (6.0) 119 (6.8)
reast tenderness or pain 108 (6.8) 10 (6.6) 118 (6.7)
elvic discomfort or pain 103 (6.4) 3 (2.0) 106 (6.1)
epression or depressed
mood
86 (5.4) 8 (5.3) 94 (5.4)
ood changes 84 (5.3) 7 (4.6) 91 (5.2)
Includes migraine headaches which occurred in 38 (2.4%) women
6–35 years old and 4 (2.6%) women 36–45 years old.
able 3
S-related⁎ adverse events with incidence ≥2% in LNG20 users over 3
ears [n (%)].
16–35 years old
(n=1600)
36–45 years old
(n=151)
Total
(n=1751)
cne 101 (6.3) 4 (2.7) 105 (6.0)
S expulsion 56 (3.5) 6 (4.0) 62 (3.4)
yspareunia 48 (3.0) 1 (0.7) 49 (2.8)
reast tenderness 30 (1.9) 5 (3.3) 35 (2.0)
ysfunctional uterine
bleeding
14 (0.9) 4 (2.7) 18 (1.0)
Relatedness determined by the principal investigator at the study site.
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of the 10 infections occurred during the first year for a 1-year
pelvic infection rate of 0.51% (95%CI 0.18, 0.85%). Only three
of the 1751 (0.2%) participants had the IUS removed for a pelvic
infection (2 PID, 1 endometritis). Chlamydia testing was
positive in 23 of 1751 (1.3%) subjects at baseline, none ofwhom
developed pelvic infection.
Of the 661 (38.5%) women who discontinued LNG20 use
during the study period, 255 met criteria to be followed for
return of spontaneous menses. Almost all had a menses
within 2 months (n=241, 94.6%) or 3 months (n=248,
97.3%) following LNG20 discontinuation. Of the 68 women
followed for fertility after LNG20 discontinuation, 48
(70.6%) conceived spontaneously within 6 months and 59
(86.8%) within 12 months. The median time to conception
was 4 months.T
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14. Discussion
LNG20 was highly effective at preventing pregnancy
consistent with methods the CDC considers the most
effective contraceptive options [14]. ACCESS IUS is the
first Phase 3 pivotal hormonal IUS trial conducted
exclusively in the U.S. The study was designed to
demonstrate the efficacy and safety of LNG20 for at least
7 years of intended use. This report captures data for the
3-year indication for use. Data from subsequent planned
years of use will be summarized in future reports. Because
study participants entered the trial on a rolling basis and all
participants have not yet reached the same duration of use,
complete year-by-year data on continuation rates and other
outcomes are not finalized in this report.
This clinical trial aimed to mirror the demographics of
U.S. women likely to use this method of contraception in the
U.S., enrolling a broad range of sexually active nulliparous
and parous women at public sector, university and private
centers. Enrollment in this trial was not restricted by weight/
BMI, race or parity and included women from 16 to 45 years
of age. The characteristics of women enrolled parallels the
2010 U.S. census with respect to Hispanic ethnicity (16.3%
census and 14.7% study), African-American race (12.6%T
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and 78.4% study) [15].
This study enrolled a substantial number of nulliparous
participants, representing 57.7% of the study efficacy
population. This number was not a result of targeted
recruitment and thus may represent the interest of nulliparous
U.S. women in using highly effective contraceptives such as
an IUS. Notwithstanding the number of nulliparous
participants, nearly all (98.7%) LNG20 placement attempts
were successful.
The most common reason for discontinuation was IUS
expulsion, occurring in 3.5% of ACCESS IUS participants.
Most expulsions occurred in the first year, consistent with
expulsion timing seen with other IUDs [16–18]. A similar
expulsion rate (4.2%) was reported in a European study to
evaluate the safety and efficacy of LNG20 (under the brand
name Levosert™) in women with menorrhagia [19].
Expulsions occurred more frequently in parous participants,
which may partly account for the lower overall expulsion
rate as this study had relatively fewer parous participants. A
recent prospective trial including 5403 U.S. women using an
IUD also demonstrated a statistically significantly higher rate
of expulsion in parous as compared to nulliparous women
(11.4% vs. 8.4%, pb.001) over 36 months of follow-up [20].
The 1-year pelvic infection rate in this study of 0.51% is
similar to the 0.54% rate reported through 90 days after IUD
placement in a group of 57728 women who had IUD
placement through a large Northern California Health
Maintenance Organization [21]. Unlike results reported
among women in populations not screened for STIs [22]
we did not find any suggestion of an increased risk of pelvic
infection in the first 20 days following insertion.
Ovarian cysts were reported as adverse events in 3.4% of
LNG20 participants. This study only collected data on
women who were symptomatic as would be appropriate in
clinical care of women with an IUS; routine ultrasound
surveillance for asymptomatic and clinically non-significant
ovarian cysts was not performed. Most ovarian cysts found
on routine ultrasound examination in women using hormonal
intrauterine contraceptives are asymptomatic and clinically
non-significant [23].
Based on the findings of this pivotal Phase 3 study,
LNG20 is a highly effective and safe intrauterine contracep-
tive in a broad range of women for up to 3 years. LNG20
meets the criteria defined by the CDC and the World Health
Organization for highly effective contraceptive methods.
The LNG20 will address some of the barriers that have
previously limited full access to intrauterine contraceptives.
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